Literature DB >> 28840521

Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma.

Jian Zheng1, Ken Seier2, Mithat Gonen2, Vinod P Balachandran1, T Peter Kingham1, Michael I D'Angelica1, Peter J Allen1, William R Jarnagin1, Ronald P DeMatteo3.   

Abstract

BACKGROUND: Preoperative serum inflammatory markers have been correlated with outcome after resection of hepatocellular carcinoma (HCC), but studies have had conflicting results. This study aimed to evaluate the association of six inflammatory markers with recurrence-free survival (RFS), overall survival (OS), and microvascular invasion (MVI), a well-known prognostic factor.
METHODS: This study investigated 370 patients who underwent resection of HCC from 1992 to 2016, retrospectively evaluating their inflammatory indices and individual components including their neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), prognostic nutritional index (PNI), aspartate aminotransferase-to-platelet ratio index (APRI), and aspartate aminotransferase-to-neutrophil ratio index (ANRI). Uni- and multivariate analyses were performed to evaluate these markers for RFS, OS, and MVI.
RESULTS: The median RFS was 23 months, and the median OS was 60 months. Factors independently associated with worse RFS were higher PLR and alpha-fetoprotein level, male gender, and the presence of MVI as well as multiple nodules. Factors independently associated with worse OS were higher PLR and international normalized ratio, male gender, older age, presence of MVI and multiple nodules, larger tumor, presence of cirrhosis, and absence of steatosis. The study identified MVI in 47% of the patients. Lower level of albumin, higher level of alpha-fetoprotein, and larger tumor on preoperative imaging were independently associated with MVI.
CONCLUSIONS: This largest Western series to evaluate the utility of preoperative inflammatory markers in patients with HCC found that only PLR was associated with RFS and OS and that albumin was associated with MVI.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28840521     DOI: 10.1245/s10434-017-6060-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  25 in total

1.  C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors.

Authors:  Brian I Carr; Hikmet Akkiz; Vito Guerra; Oguz Üsküdar; Sedef Kuran; Ümit Karaoğullarından; Salih Tokmak; Tuğsan Ballı; Abdulalh Ülkü; Tolga Akçam; Anıl Delik; Burcu Arslan; Figen Doran; Kendal Yalçın; Engin Altntaş; Ayşegül Özakyol; Mehmet Yücesoy; Halil İbrahim Bahçeci; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necat Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

2.  A Low Neutrophil to Lymphocyte Ratio Before Preoperative Chemotherapy Predicts Good Outcomes After the Resection of Colorectal Liver Metastases.

Authors:  Rui Mao; Jian-Jun Zhao; Xin-Yu Bi; Ye-Fan Zhang; Zhi-Yu Li; Zhen Huang; Jian-Guo Zhou; Hong Zhao; Jian-Qiang Cai
Journal:  J Gastrointest Surg       Date:  2018-07-31       Impact factor: 3.452

3.  Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.

Authors:  Isabel Theresa Schobert; Lynn Jeanette Savic; Julius Chapiro; Khaled Bousabarah; Evan Chen; Fabian Laage-Gaupp; Jonathan Tefera; Nariman Nezami; MingDe Lin; Jeffrey Pollak; Todd Schlachter
Journal:  Eur Radiol       Date:  2020-05-19       Impact factor: 5.315

4.  Using deep learning to predict microvascular invasion in hepatocellular carcinoma based on dynamic contrast-enhanced MRI combined with clinical parameters.

Authors:  Danjun Song; Yueyue Wang; Wentao Wang; Yining Wang; Jiabin Cai; Kai Zhu; Minzhi Lv; Qiang Gao; Jian Zhou; Jia Fan; Shengxiang Rao; Manning Wang; Xiaoying Wang
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-10       Impact factor: 4.553

5.  A Combination of Blood Lymphocytes and AST Levels Distinguishes Patients with Small Hepatocellular Carcinomas from Non-cancer Patients.

Authors:  Brian I Carr; Harika Gozukara Bag; Volkan Ince; Sami Akbulut; Veysel Ersan; Sertac Usta; Burak Isik; Zeki Ogut; Adem Tuncer; Sezai Yilmaz
Journal:  J Gastrointest Cancer       Date:  2021-11-11

6.  Radiomic analysis based on multi-phase magnetic resonance imaging to predict preoperatively microvascular invasion in hepatocellular carcinoma.

Authors:  Yue-Ming Li; Yue-Min Zhu; Lan-Mei Gao; Ze-Wen Han; Xiao-Jie Chen; Chuan Yan; Rong-Ping Ye; Dai-Rong Cao
Journal:  World J Gastroenterol       Date:  2022-06-28       Impact factor: 5.374

7.  Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma.

Authors:  Norifumi Iseda; Shinji Itoh; Tomoharu Yoshizumi; Takahiro Tomiyama; Akinari Morinaga; Tomonari Shimagaki; Huanlin Wang; Takeshi Kurihara; Takeo Toshima; Yoshihiro Nagao; Noboru Harada; Yoshinao Oda; Masaki Mori
Journal:  Int J Clin Oncol       Date:  2021-07-12       Impact factor: 3.402

8.  Pre- and Postoperative Models for Prediction of Recurrence in Non-B, Non-C Hepatocellular Carcinoma.

Authors:  Kongying Lin; Qizhen Huang; Lei Wang; Jianxing Zeng; Zongren Ding; Hongzhi Liu; Jun Fu; Pengfei Guo; Zhenwei Chen; Yongyi Zeng; Weiping Zhou; Jingfeng Liu
Journal:  Front Oncol       Date:  2021-02-18       Impact factor: 6.244

9.  Effects of various interventions on the occurrence of macrovascular invasion of hepatocellular carcinoma after the baseline serum γ-glutamyltransferase stratification.

Authors:  Yao Liu; Qun Zhang; Xue Yang; Yuxin Li; Bingbing Zhu; Shuaishuai Niu; Yunyi Huang; Ying Hu; Xianbo Wang
Journal:  Onco Targets Ther       Date:  2019-02-28       Impact factor: 4.147

10.  A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma.

Authors:  Yao Liu; Le Sun; Fangyuan Gao; Xue Yang; Yuxin Li; Qun Zhang; Bingbing Zhu; Shuaishuai Niu; Yunyi Huang; Ying Hu; Ying Feng; Yuyong Jiang; Xianbo Wang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.